Amarin Corporation plc

AMRN

US0231112063

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:52:51 2024-05-15 EDT			5-day change	1st Jan Change
0.931 ^USD	+2.33%		+7.83%	+6.95%

05-13	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	MT
05-10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT

Amarin Corporation plc authorizes a Buyback Plan.

May 30, 2024

The Board of Directors of Amarin Corporation plc has authorized a buyback plan on May 1, 2024.

Latest news about Amarin Corporation plc

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	05-13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	05-10	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	05-08	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	05-07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	05-06	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	05-01	MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M	05-01	MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares.	05-01	CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Amarin Corporation plc authorizes a Buyback Plan.	04-30	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	04-19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	04-18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	04-17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	04-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	04-10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04-09	MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	04-06	CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	04-05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04-04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	04-03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	04-02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	03-26	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	03-20	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	03-18	MT

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Amarin Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.9098 USD

Average target price

1 USD

Spread / Average Target

+9.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMARIN CORPORATION PLC	+6.95%	374M
VERTEX PHARMACEUTICALS INCORPORATED	+7.41%	111B
REGENERON PHARMACEUTICALS, INC.	+11.25%	106B
BIONTECH SE	-12.66%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.77%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.47%	12.54B
LEGEND BIOTECH CORPORATION	-24.05%	8.09B

Bio Therapeutic Drugs